Skip to content

Visual Perception Difficulties After Stroke

Accuracy and Utility of the Oxford Visual Perception Screening (OxVPS), a Screening for Visual Perception Difficulties in Stroke Survivors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05981482
Enrollment
200
Registered
2023-08-08
Start date
2023-06-20
Completion date
2026-02-28
Last updated
2024-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Visual Perception

Brief summary

The goal of this observational study is to learn how well the Oxford Visual Perception Screening (OxVPS) tool can identify stroke survivors with visual perception difficulties. The main aim is to determine the accuracy and utility of the OxVPS compared to the current gold standard assessment in stroke survivors. In other words, how well can the Oxford Visual Perception Screening tool (OxVPS) identify stroke patients with visual perception problems? Participants will completed the OxVPS and the current gold standards visual perception screening tool.

Detailed description

This is a non-experimental cross-sectional study. It aims to compare the new screening test OxVPS to the gold standard tests for visual perception difficulties. Patients will be recruited at stroke rehabilitation units at hospitals in the North East of England and in Oxfordshire. Following consent: * Participants will complete the paper version of the Oxford Visual Perception Screen OxVPS (\ 15 min). * Participants will complete screening for visual perception problems with a validated screening tool (\ 30-120 min). * Participants will complete screening for cognition alterations and sensory vision with validated screening tools. (\ 30 min) * Stroke details (time since stroke, severity) and demographic data (age, socio-economic status) will be collected to evaluated representativeness of the sample.

Interventions

DIAGNOSTIC_TESTOxVPS

Comparing a new screening tool, the Oxford visual perception screening, to the gold standard, Rivermead Perceptual Battery Assessment.

Sponsors

National Institute for Health Research, United Kingdom
CollaboratorOTHER_GOV
County Durham and Darlington NHS Foundation Trust
CollaboratorOTHER_GOV
University of Oxford
CollaboratorOTHER
Durham University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with a clinical diagnosis of stroke (ischemic stroke and/or intracerebral haemorrhage). * Within 6 weeks of confirmed stroke.

Exclusion criteria

* Insufficient understanding of English * Clinical concerns that patient is unable follow simple instructions. * Clinical concerns that patient is unable to concentrate for 15 minutes. * No capacity to provide informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Validity of OxVPSAll testing completed in 2 weeksConvergent and discriminate validity will be assessed. Convergent validity expressed as a correlation between total score on OxVPS and RPAB. Discriminate validity to be expressed as correlation between OxVPS score and scores of cognitive and sensory vision assessments. Both calculated by a non-parametric Spearman correlation and estimate a 95% confidence interval. The analysis can be completed through the cor.test function in the base package of R.
Reliability of OxVPS2 weeksThe inter-rater reliability of OxVPS will be evaluated through a Bland-Altman analysis \[26\]: we will calculate the difference in OxVPS scores between raters for each patient. Subsequently, we will plot the difference in scores as a function on the average score to evaluate a bias between the raters (mean difference) that might vary based on severity of a patient's visual perceptual problems. We will report the mean difference, standard deviation, and limits of agreement within where 95% of differences between raters fall. A t-test will indicate if the mean difference is significantly different from 0. Analyses will be performed in R with the functions from blandr package (e.g. blandr.statistics and blandr.draw) or functions from a similar package.

Countries

United Kingdom

Contacts

Primary ContactKate Cowen, PhD
kate.cowen@durham.ac.uk441913343275
Backup ContactKathleen Vancleef, PhD
kathleen.vancleef@durham.ac.uk441913340108

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026